Increased Expression of Runx2 and Osteocalcin in Freeze Dried Bovine Bone Scaffold-Secretome Mesenchymal Stem Cell (In Vitro Laboratory Experimental Research on MC3T3-E1 Pre-Osteoblast Cell Culture).

Reconstruction of maxillofacial defect still remains a challenge for oral and maxillofacial surgeons. Autograft, which has been the gold standard, has limitations and donor site morbidity. Tissue engineering combining cells, scaffold, and growth factors is expected to produce ideal bone without morbidity, with Human umbilical cord mesenchymal stem cells (HUCMSC) and bovine scaffold are promising topics. HUCMSC therapy is influenced by biomolecules including cytokines, growth factors, and microRNAs, known as secretome. This study aims to analyze the osteoinduction potential of the HUCMSC secretome in the FDBBX scaffold through the expression of Runt Related Transcription Factor-2 (RUNX2) and Osteocalcin (OCN) markers. Objectives to analyze the increased expression of RUNX2 and OCN of MC3T3-E1 preosteoblast cells that were seeded into FDBBX scaffold after application of the HUCMSC secretome compared to scaffold without secretome. The study was an in vitro laboratory experiment. The first group was FDBBX scaffold after HUCMSC secretome application and the second group was FDBBX without secretome. The analysis of the RUNX2 and OCN expression of MC3T3-E1 pre-osteoblast cells that attached to the scaffold was conducted on days 7, 14 and 21 using RT-PCR method. Independent T test was conducted as a Statistical test to analyze the differences between groups, and One way ANOVA test was conducted to analyze the difference between time. The difference analysis was considered significant when p<0,05. The Independent T test result showed that the expression of RUNX2 and OCN in FDBBX scaffold after HUCMSC secretome application was significantly higher than scaffold without secretome (P=0,039; P=0,025). The expression of RUNX2 and OCN of MC3T3-E1 pre-osteoblast cells in the FDBBX scaffold after HUCMSC secretome application was higher than the scaffold without secretome application. [ABSTRACT FROM AUTHOR]